{"disease":{"id":"macular-degeneration-wet","name":"macular degeneration wet"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07496567","title":"A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":960,"lead_sponsor_name":"EyeBiotech Ltd.","has_results":false},{"nct_id":"NCT07440225","title":"A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":960,"lead_sponsor_name":"EyeBiotech Ltd.","has_results":false},{"nct_id":"NCT06190093","title":"A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects with Neovascular Age-related Macular Degeneration (AMD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":400,"lead_sponsor_name":"Outlook Therapeutics, Inc.","has_results":false},{"nct_id":"NCT07482176","title":"Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":284,"lead_sponsor_name":"Adverum Biotechnologies, Inc.","has_results":false},{"nct_id":"NCT06856577","title":"Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":284,"lead_sponsor_name":"Adverum Biotechnologies, Inc.","has_results":false},{"nct_id":"NCT03834753","title":"A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":228,"lead_sponsor_name":"Outlook Therapeutics, Inc.","has_results":false},{"nct_id":"NCT06717139","title":"Recurrence and Predictive OCT Biomarkers in Quiescent Neovascular AMD","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":220,"lead_sponsor_name":"St. Erik Eye Hospital","has_results":false},{"nct_id":"NCT04516278","title":"A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":195,"lead_sponsor_name":"Outlook Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03423823","title":"Ziv-aflibercept Efficacy in Better Regulating AMD","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Kapil Kapoor","has_results":false},{"nct_id":"NCT03844074","title":"A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"Outlook Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04832724","title":"RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT05324150","title":"M Charts Versus Amsler Test in Evaluating Metamorphopsia in nAMD","phase":"","overall_status":"COMPLETED","enrollment_count":57,"lead_sponsor_name":"Ospedale Santa Croce-Carle Cuneo","has_results":false},{"nct_id":"NCT03034772","title":"Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"Wills Eye","has_results":true},{"nct_id":"NCT04504123","title":"MMP-9 Inhibition for Recalcitrant Wet AMD","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"University of Iowa","has_results":false},{"nct_id":"NCT03066258","title":"Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"REGENXBIO Inc.","has_results":true},{"nct_id":"NCT06704009","title":"NT-101 Topical Ophthalmic Solution in Patients With Wet AMD","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":30,"lead_sponsor_name":"NexThera Co., Ltd.","has_results":false},{"nct_id":"NCT07255885","title":"CRYSTALSIGHT: ''Cohort 1.5\" Clinical Investigation Study With OCCUTRACK and Tan Tock Seng Eye Clinic to Further Develop Remote Monitoring of Maculopathy at Home Using Artificial Intelligence for Eye Tracking","phase":"","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Tan Tock Seng Hospital","has_results":false},{"nct_id":"NCT03954626","title":"Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06888492","title":"To Evaluate the Safety and Preliminary Efficacy of Intravitreal EXG202 Injection in Patients with Wet (neovascular) Age-related Macular Degeneration (wAMD)","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":8,"lead_sponsor_name":"Guangzhou Jiayin Biotech Ltd","has_results":false},{"nct_id":"NCT06398080","title":"An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting","phase":"","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false}],"total":20},"guidelines":[],"source":"Drug Landscape verified database"}